Glioma Market OverviewA glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mainly occur in the brain and, rarely, in the spinal cord. Glioma Epidemiology Insights (2022)<ul><li>The Total Glioma incident cases in the United States were ~19K cases in 2022</li><li>Glioblastoma contributed to the highest number of glioma cases</li><li>Around 36% cases were contributed by 60–74 years age group</li><li>Grade IV accounted for the highest number of incident cases</li></ul> Glioma Epidemiology Segmentation in the US from 2019 to 2032<ul><li>Total Incident Population</li><li>Grade-specific Incident Population</li><li>Type-specific Population of High-grade Glioma</li><li>Type-specific Population of Low-grade Glioma</li><li>Age-specific Population</li><li>Glioma Cases Based on Molecular Alterations</li></ul> <a href="https://www.delveinsight.com/report-store/glioma-market-insight" rel="noopener noreferrer" target="_blank" style="background-color: transparent; color: rgb(17, 85, 204);">Glioma Market</a> Insight (2022)The Glioma Market size in the US was valued ~USD 600 million in 2022 Glioma Market Strengths<ul><li>Rise in the aging population</li><li>Improvement in genomics and proteomics</li></ul> Glioma Market Opportunities<ul><li>Increasing incidence trend</li><li>Substantial market opportunity for key players</li></ul> Glioma Emerging Drugs and Key Companies<ul><li>Regorafenib: Bayer</li><li>ONC201: Chimerix</li><li>AV-GBM-1: Aivita Biomedical</li><li>Enzastaurin (DB-102): Denovo Biopharma</li><li>DCVax-L: Northwest Therapeutics</li><li>Ofranergene Obadenovec (VB-111): VBL Therapeutics</li><li>LAM561 (2-OHOA): Laminar Pharmaceuticals</li><li>MEDI4736 (durvalumab): MedImmune</li><li>Tasadenoturev (DNX-2401): DNAtrix</li><li>ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics</li><li>IGV-001: Imvax</li><li>SurVaxM: MimiVax</li><li>Berubicin: CNS Pharmaceuticals</li><li>GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)</li><li>Lerapolturev + Pembrolizumab: Istari Oncology</li><li>SONALA-001 + Exablate 2.0 Device: SonALAsense</li><li>VAL-083 (dianhydrogalactitol): Kintara Therapeutics</li><li>Pomalidomide: Bristol Myers Squibb</li><li>MDNA55: Medicenna Therapeutics</li><li>BMX-001: BioMimetix</li><li>Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp &amp; Dohme</li><li>Paxalisib (GDC-0084): Kazia Therapeutics</li><li>OKN-007: Oblato</li><li>Temferon: Genenta Science</li><li>EO2401: Enterome</li><li>INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals</li><li>Selinexor (KPT-330): Karyopharm Therapeutics</li><li>VBI-1901: VBI Vaccines</li><li>NOX-A12 (Olaptesed Pegol): TME Pharma</li><li>Tovorafenib (DAY101): Day One Biopharmaceuticals</li><li>Vorasidenib (AG-881): Servier</li><li>Eflornithine: Orbus Therapeutics</li><li>TVI-Brain-1: TVAX Biomedical</li><li>AB-218: AnHeart Therapeutics</li><li>BGB-290: Beigene</li><li>Mirdametinib: SpringWorks Therapeutics</li><li>FT-2102 (Olutasidenib): Forma Therapeutics</li><li>Vinblastine + Bevacizumab: Hoffmann-La Roche</li><li>Cobimetinib: Hoffmann-La Roche</li><li>PEMAZYRE (Pemigatinib): Incyte Corporation</li><li>VERZENIO (abemaciclib): Eli Lilly, and others</li></ul>

Glioma Market (US)

Glioma Market Infographic (US)

Glioma Infographic provides deatiled analysis of the Symptoms, Treatment, epidemiology, companies, drugs, developments in a short guide to understand the problem and market landscape in the US market.